Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in under-the-radar growth stocks can be a great way to gain exposure to companies that have the potential to outperform the market. By investing in these stocks, investors can capitalize on opportunities that may no...
InMode Ltd. ( NASDAQ: INMD ) dropped for the second straight session on Friday as the Israel-based MedTech company received the first Hold rating on Wall Street after Needham downgraded it from Buy, citing its Q4 2022 results. According to Seeking Alpha’s Wall Street ratings, I...
Sometimes the best opportunities are found in the laggards. Take medical technology (or medtech) stocks, for example. As a group, medtech stocks haven't performed well over the last year. However, their long-term potential should be great. Two underperforming medtech stocks especially stand o...
Image source: The Motley Fool. InMode (NASDAQ: INMD) Q4 2022 Earnings Call Feb 14, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: InMode (INMD) Q4 2022 Earnings Call Transcript
InMode Ltd. (INMD) Q4 2022 Results Conference Call February 14, 2023 08:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and Chief Executive Officer Dr. Michael Kreindel - Co-Founder and Chief Technology Officer Yair...
Following a four-day decline, the shares of Israel-based MedTech company InMode Ltd. ( NASDAQ: INMD ) gained on Tuesday as the company's Q4 2022 results exceeded Street forecasts despite underwhelming earnings guidance. The company focused on cosmetic procedure technologies reported $...
InMode press release ( NASDAQ: INMD ): Q4 Non-GAAP EPS of $0.78 beats by $0.09 . Revenue of $133.57M (+20.8% Y/Y) beats by $3.93M . InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 83% of qua...
Summary InMode Ltd. is filling a treatment gap in the market with innovative, minimally invasive cosmetic procedure technologies. Most of InMode’s revenue comes from growing adoption of devices. Soon, though, sales will be primarily to update its installed unit base as growth ste...
Summary Although INMD's return on equity has decreased over the years, it still remains very attractive relative to most of the firms in the health care equipment industry. While the profit margin has contracted somewhat in 2022, due to the challenging macroeconomic environment, it has ...
Summary InMode Ltd. has 80%+ gross margins and 40%+ operating margins within a growing industry. The market is overestimating short-term worries that likely won't have a material effect on long-term cash flows. On both a relative basis and through a discounted cash flow, I estimate ...
News, Short Squeeze, Breakout and More Instantly...
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling PR Newswire IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technolog...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...